Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Pluvia who wrote (1664)	2/12/1999 7:05:00 AM
From: Mao II	Read Replies (1) \| Respond to of 2135

Pluvia: This is not news. By the way, ENMD's immediate prospects have nothing to do with earth or science or corporate timetables or company fundamentals. Everybody knows this, or should. This stock right now and for who knows how many minutes or hours or days etc into the future, is trading on fantasy. By the way, did you short overnight? M2

To: Pluvia who wrote (1664)	2/12/1999 9:16:00 AM
From: ztect	Respond to of 2135

Pluvia... Per release... "...Lehman Brothers analyst, Dr. Eric Ende, said favorable results for the two drugs have only been seen in mice and not in people, making it far too early to bank on EntreMed's discoveries..." Don't they have to test it on mice before they can test it on people? Ende's statement seems like maybe just a very justifiably cautious one, though not necessarily a derisive one. What "phase" exactly is the drug in, do you know? Has there been any experimental unpublicized (for liability reasons) use of this drug that anyone knows about? What is the plan for clinical testing? Plus does this company's product only work on certain types of cancer? Since a cancer cell isn't a cancer cell isn't a cancer cell, the just asked question seems pretty critical when accessing "the competition". For example, lung cancer (I believe which involves "oat cells".....md's help!!! clear up any of my mistakes) presents and metastasizes at different rates than the cell types for pancreatic, ovarian, or stomach cancers.....thus there made be a need for a variety of products to combat different cancerous types of tumors .... Don't you think this is, at least, a possibility? z